Literature DB >> 17923803

Pegvisomant in acromegaly: why, when, how.

A Colao1, G Arnaldi, P Beck-Peccoz, S Cannavò, R Cozzi, E degli Uberti, L De Marinis, E De Menis, D Ferone, V Gasco, A Giustina, S Grottoli, G Lombardi, P Maffei, E Martino, F Minuto, R Pivonello, E Ghigo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17923803     DOI： 10.1007/BF03347452

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  31 in total

1.  Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant.

Authors:  Pietro Maffei; Chiara Martini; Claudio Pagano; Nicola Sicolo; Francesco Corbetti
Journal:  Ann Intern Med       Date:  2006-08-15       Impact factor: 25.391

Review 2.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

Authors:  John S Bevan
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

3.  Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

Authors:  A J van der Lely ; A Muller; J A Janssen; R J Davis; K A Zib; J A Scarlett; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.

Authors:  Jens Otto Lunde Jørgensen; Ulla Feldt-Rasmussen; Jan Frystyk; Jian-Wen Chen; Lars Østergård Kristensen; Claus Hagen; Hans Ørskov
Journal:  J Clin Endocrinol Metab       Date:  2005-07-26       Impact factor: 5.958

5.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

6.  Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

Authors:  Pamela U Freda; Laurence Katznelson; Aart Jan van der Lely; Carlos M Reyes; Shouhao Zhao; Daniel Rabinowitz
Journal:  J Clin Endocrinol Metab       Date:  2005-05-10       Impact factor: 5.958

Review 7.  Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

Authors:  J J Kopchick; C Parkinson; E C Stevens; P J Trainer
Journal:  Endocr Rev       Date:  2002-10       Impact factor: 19.871

8.  A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Authors:  Shlomo Melmed; Richard Sternberg; David Cook; Anne Klibanski; Philippe Chanson; Vivien Bonert; Mary Lee Vance; David Rhew; David Kleinberg; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2005-04-12       Impact factor: 5.958

9.  Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.

Authors:  Gemma Sesmilo; Wesley P Fairfield; Laurence Katznelson; Karen Pulaski; Pamela U Freda; Vivien Bonert; Eleni Dimaraki; Stavros Stavrou; Mary Lee Vance; Douglas Hayden; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

Review 10.  Predictors and rates of treatment-resistant tumor growth in acromegaly.

Authors:  G M Besser; P Burman; A F Daly
Journal:  Eur J Endocrinol       Date:  2005-08       Impact factor: 6.664
View more
  21 in total

Review 1.  The Interplay Between Pituitary Health and Diabetes Mellitus - The Need for 'Hypophyseo-Vigilance'.

Authors:  Saptarshi Bhattacharya; Sanjay Kalra; Deep Dutta; Deepak Khandelwal; Rajiv Singla
Journal:  Eur Endocrinol       Date:  2019-10-18

2.  ACROSTUDY: the Italian experience.

Authors:  S Grottoli; P Maffei; F Bogazzi; S Cannavò; A Colao; E Ghigo; R Gomez; E Graziano; M Monterubbianesi; P Jonsson; L De Marinis
Journal:  Endocrine       Date:  2014-08-23       Impact factor: 3.633

3.  The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: what to keep and what to amend?

Authors:  A Colao; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

Review 4.  Potential role of type I interferons in the treatment of pituitary adenomas.

Authors:  Giovanni Vitale; Michele Caraglia; Peter M van Koetsveld; Paola Maroni; Monica Marra; Annamaria Colao; Steven W J Lamberts; Francesco Cavagnini; Leo J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-06       Impact factor: 6.514

5.  How to improve effectiveness of pegvisomant treatment in acromegalic patients.

Authors:  M Ragonese; S Grottoli; P Maffei; A Alibrandi; M R Ambrosio; G Arnaldi; A Bianchi; S Puglisi; M C Zatelli; L De Marinis; E Ghigo; A Giustina; F Maffezzoni; C Martini; L Trementino; S Cannavo
Journal:  J Endocrinol Invest       Date:  2017-10-28       Impact factor: 4.256

6.  Managing impaired glucose metabolism in acromegalic subjects.

Authors:  V Pezzino; C Sipione; P Tita; R Vigneri
Journal:  J Endocrinol Invest       Date:  2009-07-21       Impact factor: 4.256

7.  Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction.

Authors:  Marta Ragonese; Angela Alibrandi; Gianluca Di Bella; Ignazio Salamone; Soraya Puglisi; Oana Ruxandra Cotta; Maria Luisa Torre; Francesco Ferrau; Rosaria Maddalena Ruggeri; Francesco Trimarchi; Salvatore Cannavo
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

8.  Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.

Authors:  S Cannavo; F Bogazzi; A Colao; L De Marinis; P Maffei; R Gomez; E Graziano; M Monterubbianesi; S Grottoli
Journal:  J Endocrinol Invest       Date:  2015-04-28       Impact factor: 4.256

9.  Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.

Authors:  E Ghigo; B M K Biller; A Colao; I A Kourides; N Rajicic; R K Hutson; L De Marinis; A Klibanski
Journal:  J Endocrinol Invest       Date:  2009-12-04       Impact factor: 4.256

10.  Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly.

Authors:  A Taslipinar; E Bolu; L Kebapcilar; M Sahin; G Uckaya; M Kutlu
Journal:  Med Oncol       Date:  2008-07-29       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.